199
Participants
Start Date
January 31, 2006
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2008
n-3 PUFAs
1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
Placebo
1.0 g of olive oil,one capsule twice a day
RASS inhibitors and/or RAS blockers
Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
Amiodarone
Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
Arrhytmias and Heart failure Unit-Spedali Civili Hospital, Brescia
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
OTHER